Nicox Updates on Fera Pharmaceuticals’ Continuing Evaluation of Naproxcinod
b'Nicox SA (Euronext Paris: FR0013018124, COX), an international ophthalmology company, and Fera Pharmaceuticals, a privately-held, U.S. specialty pharmaceutical company, today provided an update on Fera\xe2\x80\x99s evaluation of naproxcinod for future development.
- b'Nicox SA (Euronext Paris: FR0013018124, COX), an international ophthalmology company, and Fera Pharmaceuticals, a privately-held, U.S. specialty pharmaceutical company, today provided an update on Fera\xe2\x80\x99s evaluation of naproxcinod for future development.
- Nicox and Fera entered into an agreement in December 2015, amended in September 2018 and December 2020, which granted Fera exclusive rights to develop and commercialize naproxcinod for the U.S. market.
- A broad clinical package already exists for naproxcinod in osteoarthritis, including three phase 3 trials with over 2,700 patients.\nFera Pharmaceuticals is a privately held company.
- Nicox disavows any obligation to correct or to update the information contained in analyst reports.\n'